Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia

Full text
Show less -
Gadelha, A. [1] ; Vendramini, A. M. [2] ; Yonamine, C. M. [2] ; Nering, M. [2] ; Berberian, A. [1] ; Suiama, M. A. [2] ; Oliveira, V. [3] ; Lima-Landman, M. T. [2] ; Breen, G. [4] ; Bressan, R. A. [1] ; Abilio, V. [2, 1] ; Hayashi, M. A. F. [2, 1]
Total Authors: 12
[1] Univ Fed Sao Paulo, Integrated Lab, Clin Neurosci & Schizophrenia Program, Dept Psiquiatria, BR-04044020 Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Dept Farmacol, BR-04044020 Sao Paulo - Brazil
[3] Univ Fed Sao Paulo, Dept Biofis, BR-04044020 Sao Paulo - Brazil
[4] Kings Coll London, Inst Psychiat, Med Res Council Social Genet & Dev Psychiat Ctr, London WC2R 2LS - England
Total Affiliations: 4
Document type: Journal article
Web of Science Citations: 11

In schizophrenia (SCZ), higher angiotensin I-converting enzyme (ACE) levels have been reported in patient's blood and cerebrospinal fluid (CSF). Hereby, we propose to explore whether the ACE activity levels are associated to cognitive performance in SCZ. Seventy-two patients with SCZ or schizoaffective disorder diagnosis, and 69 healthy controls (HCs) underwent a cognitive battery with parallel collection of peripheral blood samples to measure ACE activity. Significant higher ACE activity levels were confirmed in the plasma of SCZ patients compared with HCs (Student's t=-5.216; P<0.001). ACE activity significantly correlated to Hopkins delayed recall measures (r=-0.247; P=0.004) and Hopkins total (r=-0.214; P=0.012). Subjects grouped as high ACE activity (above average) had worse performance compared with low ACE activity level group for Hopkins delayed recall measure, even after correction for clinical condition, age, gender and years of education (P=0.029). The adjusted R squared for this final model was 0.343. This result was evident only comparing extreme groups for ACE activity, when splitting the sample in three groups with similar number of subjects. To clarify this finding, we performed an evaluation of the cognitive performance of transgenic mice with three copies of ACE gene in novel object recognition (NOR) test, which showed that such animals presented impairment in NOR (P<0.05) compared with two copies of wild-type animals. The results observed in SCZ patients and animal model suggest both the association of ACE to cognitive deficits in SCZ. This finding may support the evaluation of novel treatment protocols and/or of innovative drugs for specific intervention of cognitive deficits in SCZ envisioning concomitant ACE activity and behavior evaluations. (AU)

FAPESP's process: 13/13392-4 - Evaluation of the use of analogs of crotamine for diagnosis or therapy
Grantee:Mirian Akemi Furuie Hayashi
Support Opportunities: Regular Research Grants
FAPESP's process: 11/50740-5 - Prevention in schizophrenia and bipolar disorder from neuroscience to the community: a multiphase, multimodal and translational platform for research and intervention
Grantee:Rodrigo Affonseca Bressan
Support Opportunities: Research Projects - Thematic Grants